CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
2 research outputs found
Recommended from our members
Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3 -ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study
Author
Amadori Sergio
Dombret Herve
+11 more
Erba Harry Paul
Gammon Guy
Ge NanXiang
Gokmen Sugun
Hanyok James
Levis Mark J.
Macintyre Susan
Mires Derek Edward
Schlenk Richard F
Sekeres Mikkael A.
Zernovak Oleg
Publication venue
Publication date
20/05/2016
Field of study
No full text
University of Miami: Scholarship Miami
Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3
Author
Derek Edward Mires
Guy Gammon
+11 more
Harry Paul Erba
Herve Dombret
James Hanyok
Mark J. Levis
Mikkael A. Sekeres
NanXiang Ge
Oleg Zernovak
Richard F Schlenk
Sergio Amadori
Sugun Gokmen
Susan Macintyre
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref